Impact of THN102 on Attention, Wakefulness and Cognitive Performance During Total Sleep Deprivation
Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
Study Objectives: THN102 is a new combination between modafinil and flecainide low-dose, a
documented glial connexin inhibitor. Efficacy of THN102 was compared to modafinil and to
placebo on parameters impaired by total sleep deprivation (SD, lasting 40h).
Methods: 20 healthy male subjects participated in a double-blind, randomised,
incomplete-block 3-period cross-over trial involving 5 treatments (n=12 per group): placebo
(PBO), modafinil 100 mg (MOD), and combinations THN102 (modafinil 100 mg and 1, 3 or 9 mg
flecainide as THN1, THN3 and THN9), as 3 oral doses over 18h.